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Liquid Biopsy Approach in Precision Oncology 
Abstract: 
Liquid biopsy serves as a tool to analyse cell-free nucleic acids (cfNAs) and circulating tu-
mour cells (CTCs) in blood or other body fluids in individuals with cancer. These are con-
sidered promising diagnostic and prognostic biomarkers but new discoveries are still being 
made in regard to their heterogeneity, therefore it is critical to continue researching to 
demonstrate a clinical advantage in precision oncology. For now they promise to reveal mo-
lecular characterisation of tumours which can change the prognosis, monitoring and post-
therapy of cancer care. This is challenging because the technologies and methodologies are 
still not mature enough for capturing and isolating viable cells. Higher affinity and sensitive 
techniques including a combination of these may result in an efficient characterisation of 
CTCs and cfNAs. From pre-treatment of blood samples to post-analysis of isolated markers 
it is required to standardize and regulate methods in order to prove clinical utility, as of now 
this remains in the experimental phase. Microfluidic systems have become an influential tool 
in cancer studies for their capability to analyse single cells or molecules and its integration 
with other techniques, miniaturization and fast analysis which will help overcome challenges 
these biomarkers face to eventually replace traditional biopsy with liquid biopsy.  
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Vedelbiopsia Meetodid Onkoloogias 
Lühikokkuvõte: 
Bakalaureusetöö on kirjutatud inglise keeles, kirjanduse põhjal ning on klassikalise ülesehi-
tusega koosnedes sissejuhatusest, kirjanduse ülevaatest, töö eesmärkidest, diskussioonist ja 
kokkuvõttest. Töö on esitatud 40-l leheküljel, sisaldades ka ühe joonise ja neli tabelit. Töö 
koostamisel on kasutatud 48 kirjanduse allikat. 
Töö põhisisuks on ülevaate andmine erinevatest vedelbiopsia meetoditest, mille abil saab 
vähi patsientidel analüüsida veres või muudes kehavedelikes ringlevaid rakuvabasid nuk-
leiinhappeid (cfNAd) ja ringlevaid vähirakke (CTCd). Neid peetakse paljutõotavateks diag-
nostilisteks ja prognostilisteks biomarkeriteks, mis võimaldavad senisest paremini ning 
mitte-invasiivselt iseloomustada kasvajaid molekulaarsel tasemel. See on väga oluline vähi 
patsientide personaalses ravis, võimaldades kasvajate tekke ja arengu paremat jälgimist ning 
ravi. Töös on kirjeldatud cfNA-de ja CTC-de olemust, päritolu, eraldamist ning analüüsiks 
kasutatavaid tehnoloogiaid. Samuti on võrreldud vedelbiopsia kasutatavust ja perspektiive 
tänapäeval traditsiooniliselt rakendatava klassikalise biopsia meetoditega. Arutelu osas on 
antud ülevaade meetodite hetkeseisust ja võimalikest arengutest tulevikus. 
Võtmesõnad: 
Vedelbiopsia, vähidiagnoos, veres ringlevad vähirakud, veres ringlev rakuvaba DNA 
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TERMS, ABBREVIATIONS AND NOTATIONS 
cDNA  Complementary DNA 
cfDNA  Circulating cell-free DNA 
cffDNA Circulating fetal DNA  
cfNAs  Circulating cell-free Nucleic Acids 
cfRNA  Cell-free RNA 
CK  Cytokeratin 
CRC   Circulating rare Cells 
CTCs  Circulating tumour Cells  
ctDNA  Circulating tumour DNA 
CTM   Circulating tumour microemboli 
ECM  Extracellular matrix 
EMT  Epithelial to mesenchymal transition 
EMVs  Extracellular membrane vesicles 
EpCAM Epithelial cell adhesion molecule  
FDA   US Food and Drug Administration 
IARC  International Agency for Research on Cancer 
lncRNAs Long non-coding RNAs 
LOD   Limit of detection 
miRNAs microRNAs 
mRNA  Messenger RNA 
ncRNAs Non-coding RNAs 
NGS   Next Generation Sequencing 
NSCLC Non-small cell lung cancer 
PCR   Polymerase Chain Reaction 
POC  Point-of care 
PSMA  Prostate-specific membrane antigen 
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RHD  Rheumatic heart disease  
RNP  Ribonucleoprotein 
SERS  Surface Enhanced Raman Spectroscopy 
siRNAs Small interfering RNAs 
SNPs  Single nucleotide polymorphisms 





This thesis focuses on helping understand the current advancements on precision oncology.  
It informs about the advantages and challenges liquid biopsy has as a tool for analysing 
cancer biomarkers such as circulating cell-free nucleic acids (cfNAs) and circulating tumour 
cells (CTCs) in blood samples. The method may be useful for cancer research physicians 
and oncologists who are investing in developing or improving the diagnosis and/or therapy 
of cancer. Tumorigenesis can be associated with genetic and epigenetic modifications, some 
of which could be detected in plasma or serum as cfNAs, for this reason these biomarkers 
may be excellent. However, currently there is not a consensus on protocols, methods and 
reporting results and very little is known about their heterogeneity. For this reason, this thesis 
focuses on CTCs as it has been proven that they are the precursors of cancer metastasis and 
although their true nature is not completely understood they are able to survive and adapt in 
the circulation system inducing angiogenesis in the target tissue. Although with present 
knowledge, it is biased to name a better biomarker, cfNAs and CTCs have similar advantages 
and challenges. In general, the strategies to capture CTCs and differentiate them from other 
haematological cells are based on their physical (size, density, deformability, dielectropho-
resis) and biological (expression of biomarkers) properties, which allows analysing them 
afterwards. At the same time microfluidic systems have been incorporated in other methods 
to increase the capture, isolation and analysis of CTCs in a faster and reliable way at a single-
cell executability. In general two methods are employed in microfluidic devices, based on 
the beforementioned. Neither have proven to beat the challenges and be the preferable 
method of work and the literature suggests that an actual combination of these two may get 
physicians closer to their goal of analysing these biomarkers for their characterization. The 
goal of this literature based thesis is to give an overview of the possibilities a liquid biopsy 





1 LITERATURE REVIEW 
1.1 CANCER IN A NUTSHELL 
Cancer has always been a very serious health issue. We all know someone who has survived 
it or that unfortunately has passed away fighting it. According to the World Health Organi-
zation (WHO), cancer is ranked as the second leading cause of death in the world, being 
responsible for an estimated 9,6 million deaths in 2018. That makes, globally, 1 out of 6 
deaths be due to cancer, so this data is highly relevant and has to be taken seriously (Reboux, 
2018). Cancer is killing people across the globe on a daily basis and the numbers are increas-
ing every year. Thanks to this information, or more likely, by the concern it arises socially,  
a lot of research and effort has been put out by governments, scientists and associations who 
are trying to understand ‘cancer’ to provide novel solutions that will save the lives of future 
cancer patients.  
Cancer can affect any part of our bodies, growing abnormal cells that proliferate without 
control or limit at an exponential rate. Since the cells are not encapsulated, it can easily 
spread or adjoin to the organs closest to where it started and so on; this is known as metastasis 
and it is the reason cancer gets tougher to fight, not only because a secondary malignant 
site(s) is growing apart from the primary site but because this is the major cause of death 
from cancer (Yin et al., 2019). Cancer does not know race, age or social status. Although 
there are certain factors that will trigger tumorigenesis, the conditions that provoke cancer 
can be both dependent and independent of our lifestyle. Through research, the WHO and the 
International Agency for Research on Cancer (IARC) classify cancer causing agents. These 
can be both extrinsic and intrinsic agents, shown in table 1.  
 
Table 1. Cancer causing agents (Modified after Reboux, 2018). 
 




-Physical carcinogens, like UV and ioniz-
ing radiation. 
 
-Chemical carcinogens, such as asbestos, 
components of tobacco smoke, aflatoxin (a 
food contaminant), and arsenic (a drinking 
water contaminant). 
 
-Biological carcinogens, such as infections 





It might be redundant to include that tobacco use, alcohol abuse, not being physically active 
and having an unbalanced and unhealthy diet are major risk factors not only for cancer but 
for other noncontagious diseases.  
Diagnosing cancer requires different modes of activity or occurrence. It is absolutely neces-
sary for cancer management to get an early, sensitive and accurate diagnosis. Not only will 
it make the difference for the patients chance of survival but it will reduce the costs overall. 
For these reasons, it is important that novel technologies and approaches to identify and 
study cancer are brought up by scientists and researchers. In body fluids like blood, urine, 
cerebrospinal fluid and saliva there are cancer biomarkers that can be isolated to analyse 
tumours (Geeurickx and Hendrix, 2019). This has given physicians the opportunity to study 
cancer in a non-invasive way known as liquid biopsy, contrary to the traditional biopsy 
which is invasive and currently the efficient way to extract and study tumour material. In 
this regard, there has been a lot of effort in enabling better diagnostics and treatments for 
cancer patients. Microfluidic technology is an auspicious tool that opens the door to new 
possibilities to analyse tumours. The benefits of this technology expands to, not only the 
previously mentioned, but economically too. According to the WHO, in 2010, the estimated 
total annual cost of cancer was US$ 1,16 trillion (Reboux, 2018). The economic impact of 
cancer is also to be taken note of, as the amount is significantly high and this money can go 
towards other social branches of improvement. 
 
1.2 WHAT IS LIQUID BIOPSY? 
A relatively novel method for cancer diagnosis that is defined as the analysis of tumour 
material (for example, cells or nucleic acids) taken in a minimally invasive or non-invasive 
way through the sampling of blood or other body fluids (Wan et al., 2017). From the blood 
sample scientists are interested in specific biomarkers, particularly in CTCs and  cfNAs (cir-
culating tumour DNA, RNAs and exosomes) (Sánchez et al., 2016), shown in figure 1. It is 
promising that a blood sample can be the key to saving many lives from cancer, however, it 
is not that straightforward and it will require more years of research and new technology to 
get to this point. The level of importance in these biomarkers relies in comprehending the 
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origin of tumours and of metastasis, therefore offering scientists a better perception of tu-
mour behaviour, for both, applying a better and a more effective treatment and for keeping 
a close eye on patterned advance. 
 
Figure 1. Liquid biopsy test in a cancer patient. Modified from (Lowes et al., 2016) and (Yin 
et al., 2019). CfNAs can get isolated from plasma or serum and CTCs from cellular fraction 
of blood samples. 
 
1.2.1 DIFFERENCES TO TRADITIONAL BIOPSY 
Traditional biopsy consists of the extraction of cancerous or suspected cancerous tissue for 
identifying its nature or cause (i.e., needle biopsy, bone marrow biopsy, etc.) (Law et al., 
2020). The thing about tumours is that they are heterogenous and taking a sample from one 
specific point gives only a result for that part of the tumour. Taking many samples is not an 
option either because tissue extraction is hazardous and painful for the patient; not to men-
tion that depending on the type of cancer or its location, removal could not be possible at all. 
Moreover, this method is time consuming and pricey. Today, this is performed as the effec-
tive way to access the molecular information of the tumour. It provides essential information, 
i.e.: the histology and description of the tumour characteristics necessary to apply an efficient 
treatment. For lung cancer, for example, the biopsy followed by histology analyses will en-
able physicians to tell which type of tumour it is, such as squamous cancer, adenocarcinoma, 
small cell lung cancer, non-small cell lung cancer (NSCLC), or another, less common type 
(Shtivelman, 2017). 
Plasma and cfNAs. 
CTCs and other haematological cells. 
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1.2.2 COMPARISON AND ADVANTAGES 
In comparison with traditional biopsy, liquid biopsy offers a reduced risk of complication 
being non-invasive (or minimally), an increased ability for monitoring over an extended pe-
riod of time, the possibility to identify clonal evolution and the developments of resistances 
in cancer cells (Law et al., 2020). However, compared to traditional biopsies, liquid biopsies 
lack the advantage to determine the histology of tumours with precision, at least for now. 
Hopefully within the next couple of years liquid biopsy will be at the point of giving scien-
tists this information as for today, the available tests are limited. This defines one of the 
current limitations of liquid biopsies (Shtivelman, 2017). On a brighter note, liquid biopsies 
do not require surgery, which reduces costs. This also allows diagnosis to be more time 
efficient, and patients will avoid a traumatic experience that is sometimes a slow recovery 
with a needle stick that takes a small amount of blood. There is no comparison on that note 
considering the well-being of the patient. Furthermore the promises it has once the analysis 
results come up will overpass traditional biopsies by miles. Another important difference is 
that when a tissue sample is taken from a tumour, call it a bone marrow biopsy, for example, 
doctors are only getting a limited amount of information. Considering that by this result, 
they will determine how the cancer will be treated and give the patient an overall diagnosis 
of their situation and that tumours are in constant change, everyday evolving, the level of 
accuracy is not high. Metastatic tumours may be even more divergent from the tumour that 
seeded them, this implies that mutational analysis of solid tumours is fallible (Wan et al., 
2017). 
On the contrary, the advantage of liquid biopsy, is that it analyses cells that are shed into the 
bloodstream by all tumours present in a patient with metastatic cancer. Also, it is expected 
to give a complete picture of all mutations found in all tumours (Shtivelman, 2017). At least 
this is the goal, as for now, more research is needed to even assume that all tumours release 
the same amount of cells into the bloodstream and that taking a blood sample could not pick 
up this information equally. It is a turning point for cancer patients, as the time continues to 
pass, this technology will eventually make it feasible to experience cancer differently. The 
limitations liquid biopsy currently has, mainly, the isolation of the desired biomarkers from 
the bloodstream, will get better as genetic sequencing technology improved with the arrival 
of polymerase chain reaction (PCR) and eventually next generation sequencing (NGS) tech-
nologies, cancer cells are more thoroughly characterized (Law et al., 2020). In short, liquid 
biopsies will be beneficial for physicians to monitor the evolution of the tumour, attack it in 
the best way possible and access information when tissue samples are not accessible. Roche 
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Diagnostic’s Cobas EGFR Mutation Test version 2 is currently the only US Food and Drug 
Administration (FDA) approved liquid biopsy, and serves as a case study for the successful 
translation of this technology. The test is in adjustment of an existing tissue biopsy system 
for identifying specific mutations in NSCLC (Law et al., 2020). 
 
1.3 CELL-FREE DNA 
We owe two French physicians the acknowledgement of circulating cell-free DNA (cfDNA) 
in human blood. In 1948 Mendel and Métais first noticed it, but it was until 1977 when the 
discovery of elevated levels of cfDNA in patients with cancer was made. This discovery 
allowed physicians and scientists for further explorations into the connection between the 
two (Law et al., 2020). Circulating cell-free DNA is defined as DNA circulating in the blood-
stream that is not associated with cells (Heitzer et al., 2019). cfDNA are DNA fragments 
that can be isolated from blood plasma or serum in mammals (Grabuschnig et al., 2020) and 
it is primarily constituted of monomers that range between 150 and 200 base pairs in length 
(Raymond, 2019). Its estimated half-life may vary from several minutes to an hour or two 
giving the scenario in which it is assessed (Kustanovich et al., 2019).  
The potential of cfNAs was not of much interest in oncology at early stages of discovery. It 
was until it was demonstrated that circulating fetal DNA (cffDNA) in maternal plasma, per-
ceived the presence of Y chromosome-specific complementary DNA (cDNA) fractions and 
a gene which determines Rheumatic heart disease (RHD) in 1997, which is the non-invasive 
prenatal diagnostic (Grabuschnig et al., 2020). Moreover, it took another 18 years for tech-
nology to reach the point of testing in a non-invasive way for trisomy 21, when next-gener-
ation sequencing (NGS) became available (Pös et al., 2018). By today non-invasive prenatal 
testing of most common aneuploidies including trisomy’s 21, 18 and 13 became a well-
adapted screening method in many countries (Wan et al., 2017). 
 
1.3.1 CIRCULATING TUMOUR NUCLEIC ACIDS  
Under the term of cfNAs usually it makes reference to DNAs and RNAs. A great variation 
of cell-free nucleic acid molecules take part of multiple physiological processes which are 
not fully understood and will require years of further investigation to understand their roles. 
For this reason, cfNAs are not the biomarker of interest in this thesis, however, the most 
relevant finds are noted. cfNAs are contained in extracellular membrane vesicles (EMVs) or 
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they form ribonucleoprotein (RNP) complexes where they are protected from degradation. 
EMVs that are released from tumour cells are known to carry oncogenic factors, like nucleic 
acids, and thus are named oncosomes. When oncosomes are introduced into a recipient cell, 
it transports the cancer cells and transfers its oncogenic message across idle cells (Pös et al., 
2018). This is believed to be a propagation form of cancer and thus serving as an appropriate 
field of study in precision oncology. For this reason, nucleic acids have gained their field of 
study as biomarkers for various diseases like: neurodegenerative, infectious diseases and 
cancer (Gilboa et al., 2020). Studies demonstrated that nucleic acid biomarkers can be used 
for diagnosis, determining optimal therapy and understanding the severity of the illness 
(Salvianti et al., 2020). 
Regardless that technology has now enabled the possibility to examine forward cfNAs, there 
are still important challenges to consider with its analysis. First, they are also, like other 
biomarkers, present at a very low concentration in blood samples; this means that ultra-sen-
sitive techniques are necessary. Second, since the sample is heterogenous, it will contain 
multiple off-target nucleic acids; so there needs to be specific target molecule technologies. 
Another challenge because of this is that the measurements can mask nucleic acids of inter-
est, so ultra-sensitive and single-molecule technologies are needed for analysis (Gilboa et 
al., 2020). The immune system also prevents cfNAs to be elementary biomarkers. The quan-
tity will be influenced by degradation or the lymphatic system overall. Another natural pro-
cess by which nucleic acids are drained out of the circulation is by the kidney and the liver; 
studies have not been too precise about the half-life of cfNAs, as it ranges from 15 minutes 
to several hours (Schwarzenbach et al., 2011). Other studies show that the levels of cfNAs 
may also point out to other pathological or physiological processes that are not tumour re-
lated, like inflammations. The production of cfNAs has shown to raise in patients with can-
cerous lesions compared to not having a tumour, all the same, an increased level has also 
been reported in people with harmless lesions (Schwarzenbach et al., 2011). Thanks to novel 
technologies, today it is possible to examine further in this area, however, it was not until 
very recent that this was possible and thus there are a lot dead ends. Soon, as collective 
results come up in the databases it will be possible to use cfNAs as a complimentary, or even 
replace it, with conventional cancer diagnosis (tissue biopsy). As of now, there has not been 
many efforts to develop microfluidic tools to evaluate and isolate cfNAs (Sun et al., 2018). 
cfNAs hold a promising future in screening, diagnosis, medical prognosis, therapy and out-
come of cancer and other diseases (Pös et al., 2018). Furthermore, experiments on graft hy-
brids showed that cfNAs differentiated from somatic cells to germinal cells and pass along 
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to offspring. This made a reality the heritage of new features through cfNAs and can signify 
that they may take part in evolution mechanisms (Pös et al., 2018). This demonstrates that 
the nature of cfNAs yield in the bloodstream is not yet understood. 
 
1.3.2 ANALYSIS OF DNA 
DNA biomarkers include deletions, insertions, single nucleotide polymorphisms (SNPs), 
short tandem repeats or other variations. Other DNA biomarkers are translocations, patho-
genic DNA and mitochondrial DNA (Gilboa et al., 2020). Since cancer affects the nature of 
DNA directly at the cellular level, it is of relevance to study these changes, as they can be 
measured in the tumour (Ziegler et al., 2012). DNA analysis has major challenges to over-
come. First, the human genome was sequenced 17 years ago and is very complex, from this 
we know that there are gene sequences longer than 1000 nucleotides; this means that precise 
mapping requires long read capabilities and tools (NHGRI, 2015). Furthermore, we now 
know that the human genome has approximately three billion nucleotides, to fully under-
stand how an individual will respond to treatment it requires to analyze a large indefinite 
number of genes; which will be possible as technologies for genetic sequencing rise. For 
these biomarkers it also implies difficulties that the samples are highly diversified, as the set 
of molecules may superimpose the sequences of interest, which is why single-molecule 
methods are required to overcome and identify individual molecules.  
 
1.3.3 ANALYSIS OF RNA 
In regard to RNA, there is a vast list of types but the most common and the ones that will be 
described are: messenger RNA (mRNA) and non-coding RNAs (ncRNAs), like microRNAS 
(miRNAs), long non-coding RNAs (lncRNAs) and small interfering RNAs (siRNAs). All 
these are involved in gene expression control and regulations which makes them appropriate 
biomarkers for cancer.  
The biological process of mRNA gives it a high value for cancer diagnosis, although little is 
known, analyzing mRNA can be used for gene expression identification and illness diagnos-
tics (Le Rhun et al., 2020). However, the ratio of mRNA in samples is low and unstable due 
to degradation, which complicates its analysis (Sun et al., 2018). Technologies with high 
sensitivity are preferential, this helps overcome the low copy number of mRNAs, which does 
not surpass the hundreds of copies per cell (Gilboa et al., 2020).  
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miRNAs are involved in gene regulation and it is known that they activate or repress trans-
lation of proteins. They are short strands of ncRNA and they become abnormal in cancer, 
causing it to become more aggressive by proliferation, apoptosis, metastasis and angiogen-
esis. For this reason, scientists believe that they can give insight for diagnosis, monitoring 
and healthful remedies in cancer patients (Sohel, 2020). Due to their size, 17-25 nucleotides, 
and low levels found in samples, with reports showing femtomolar ranges, it is difficult to 
analyze them with conventional tools (Gilboa et al., 2020). In contrast, there are longer nu-
cleotide RNAs, which are >200 nucleotides. However, this does not simplify their analysis. 
lncRNAs are non-coding as well and regulate intercellular trafficking, transcriptome, chro-
mosome remodeling, etc.. They have a cancer biomarker potential because they show to 
mediate epigenetic alterations by recruiting chromatin modification factors, this leads to 
gene silencing (Ghafouri-Fard et al., 2020). Although they have promising qualities and will 
contribute to precision oncology in the future, together with siRNAs, at present days, there 
is not enough information on how they can influence the development in cancer (Ahmadzada 
et al., 2018). It must also be taken into consideration that RNA quantification requires to 
reverse transcribe the RNA to cDNA form, traditional technologies still complicate this pro-
cess; Another complication is that biologically RNA will amplify and this can sabotage the 
original amount of RNA that was intended to get analyzed. Finally, the great varieties of 
RNA come in different proportions, so it is more likely that other abundant RNA will com-
plicate the detection of the RNA of interest (Sun et al., 2018). 
 
1.4 CIRCULATING TUMOUR DNA AS A BIOMARKER 
Primary tumour cells undergo necrosis, apoptosis, phagocytosis, or cell detachment, and re-
lease tumour-derived cell-free DNA, otherwise known as circulating tumour DNA (ctDNA), 
into the bloodstream. Early detection of ctDNA via simple blood draw offers the potential 
for population-level screening, early detection, intervention, and progressive monitoring 
throughout treatment. Most of the cfDNA originates from cells of hematopoietic lineage but 
in patients with cancer it contains circulating tumour DNA which has the potential of being 
a biomarker in precision oncology. Evidence shows that ctDNA provides a well-rounded 
view of the tumour genome as it reflects DNA released from multiple tumour regions or 
different tumour foci (Heitzer et al., 2019). Table 2 points out to some favourable approaches 




Table 2. ctDNA pros and cons.  
 
Approaches  Limitations 
Suitable for analysis of specific mutations 
and copy number alterations. 
Without standardized or validated tech-
niques. 
 
Viable long-term storage for posterior 
analysis. 
Possible clinical implementation, but still 
at risk of cfDNA dilution bias. It is cur-
rently impossible to know if the lack of 
ctDNA is real or whether it is bias due to 
dilution in the cfDNA in a sample that 
does not show copy number alterations or 
mutations in the analysed gene (Puche-
Sanz et al., 2020). 
Useful for minimal residual or localized 
disease. 
Very low levels, often <0.1% (Zhang et 
al., 2019). 
 
ctDNA as a biomarker can be revealing about tumour mass, giving an overall extent of the 
disease to physicians to understand the appropriate approach to treat cancer. It has also 
shown to have prognostic value, as the presence of ctDNA after treatment, whether by ex-
traction of the tumour in surgery and/or with chemotherapy will result in predictive analysis 
associated with recurrence and poor outcome, enabling patients to be treated more effec-
tively and being able to trace their health in a timely manner (Salvianti et al., 2020). The 
idea is that cancer patients that went through chemotherapy and/or surgery to treat their can-
cer are able to know how well they are doing by analysing their ctDNA levels. As studies 
show that there is a correlation between the size of the tumour and the amount of ctDNA 
found in plasma. The magnitude of ctDNA that originates from individual cancer lesions 
depends on the anatomic location and size of the tumour; It has been estimated that, for a 
patient with a tumour of 100g in weight, 3.3% of its DNA can be released in the bloodstream 
every day. Also, the presence of CTCs and metastatic lesions can contribute to ctDNA yields 
(Zhang et al., 2019).  
An important thing to take into account is the process of drawing blood. It has to be done 
considering important factors about ctDNA. Research suggests that ctDNA has a half-time 
in the circulation, with a reported average around 15 minutes, due to rapid clearance by 
lymphatic circulation via kidneys, spleen and liver (Siravegna et al., 2019). During blood 
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collection and processing it is essential to avoid white blood cell lysis which increases dilu-
tion of tumour circulating fragments from genomic DNA derived from white blood cells 
(Siravegna et al., 2019). During enrichment, research has demonstrated that sensitivity can 
be increased on the basis of their length, which is reported to be around 132-145 base pairs, 
compared to cfDNA from normal cells being approximately 166 base-pairs (Heitzer et al., 
2019). On a brighter note, since it is known that there is low concentration of ctDNA in the 
blood, a lot of research has been done to improve analytical specificity and sensitivity. In 
recent times, the technologies for DNA isolation have been of major improvement and more 
is understood to treat the blood accordingly to get consistent results. Apart from knowing 
that ctDNA is time sensitive; transportation, processing and storage of the sample play an 
important role in the consistency of the results too, as they also affect ctDNA directly either 
by degrading it or in quantification itself. However, it is too soon to have a common proce-
dure across all laboratories, but this information has helped most research work conclude 
that it is essential to isolate plasma within an hour after blood draw to prevent cfDNA deg-
radation due to DNase activity. Purposely designed blood collection tubes for cfDNA are 
accessible from multiple providers which minimize cell lysis and stabilize the total cfDNA 
pool by the inclusion of various additives and preservatives (Siravegna et al., 2019). After 
blood draw, the procedure is a pretreatment to improve separation efficiency and this can be 
done by centrifugation or filtration, and studies show that this step may be reducing the count 
of ctDNA (Gao et al., 2020).  
All the above mentioned is great advancement for using ctDNA as a biomarker, but on the 
contrary the true nature and source of cfDNA is still unknown and open for researchers dis-
cussion. A lot of research suggests that it might be derived from dying tumour cells being 
released from apoptosis or other forms of cell death, but recent ctDNA analyses have iden-
tified somatic modifications associated with aggressive, proliferative cancer cell clones. De-
termining to what degree different tissues contribute to the composition of plasma in both 
health and disease will be critical to understanding the physiology of DNA release from cells 
into the bloodstream (Heitzer et al., 2019). In fact, there is considerable inconsistency be-
tween the studies and methodologies done to understand cfDNA composition. So far, most 
of the results have not been able to prove the exact origin or correlation between tumour 
tissue contribution and levels of ctDNA which concludes that there is very limited 
knowledge in this area and why ctDNA is not quite the favourite biomarker when it comes 




1.5 CIRCULATING TUMOUR CELLS 
Thomas Ashworth documented the first observations or findings of CTCs in 1869, where he 
identified microscopically, from a cancer patient who died due to metastatic illness what 
today is classified as circulating tumour cells (Geeurickx and Hendrix, 2019). Since then it 
was known that someday this discovery was going to help identify tumorigenesis, and it has 
taken more than a century for these efforts to reflect in something tangible.  
 
1.5.1 ORIGINS AND FREQUENCY OCCURRENCE 
The origin of CTCs remains unknown and is not fully understood. The most realistic expla-
nation is that they emerge from a primary or even secondary metastatic tissue and enter the 
bloodstream. The exact mechanism has not been proven but there are various events that add 
up to this theory, including the hypoxic tumour environment, extracellular matrix (ECM) 
remodelling, active proliferation and epithelial to mesenchymal transition (EMT) (Sun et al., 
2018). In the actuality this model suggests that CTCs travel from the tumour or the metastasis 
itself into the blood circulation and accesses nearby organs and causes the development of 
malignant growths that is, propagating it to other body parts. This makes the cancer more 
aggressive and harder to fight. This can happen at any stage of the cancer but the more ad-
vanced the state the more CTCs seem to be released; It is important to note that CTCs are 
extremely rare, with 1 CTC present for 1x10E6 – 1x10E9  blood cells (Geeurickx and 
Hendrix, 2019). They have a half-life of 1 to 2.4 hours and can be differentiated from mes-
enchymal blood cells by the expression of epithelial surface proteins, such as epithelial cell 
adhesion molecule (EpCAM) or proteins of the cytokeratin family (CKs 8, 18 and 19), or by 
their epithelial morphology (Geeurickx and Hendrix, 2019). After the CTCs are shed into 
the bloodstream they will be present for a relatively limited time, giving physicians a time 
frame to take samples. It is possible that the lasting of the CTCs is only a short time due to 
immune wipe out or apoptosis.  
In studies, it has been proven that there is already a small percentage of CTCs in blood 
analyses even before clinically diagnosed metastasis. Nonetheless, studies are not pursuant 
at all times given that cancer behaves differently in all patients, not to mention that the meth-
ods nowadays have a low sensitivity and accuracy (Sun et al., 2018). Comparatively, studies 
also demonstrate that the relation between the amount found of CTCs in the blood is propor-
tionate to the cancer status of the patient; the number can spike as the primary tumour site 
expands or alternatively downsize in response to tumour  shrinkage with efficient therapy 
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(Hiltermann et al., 2012). To date, the FDA has approved one system for clinical use that 
can detect CTCs in the blood; in 2004 the system was authorized to predict outcomes on 
breast cancer, in November 2007 and February 2008, the system was granted as well ap-
proval for colorectal and prostate cancers (Millner et al., 2013). The name of the system, by 
Menarini Silicon Biosystems (Bologna, Italy), is called CellSearch® and it is for identifica-
tion, isolation and enumeration of CTCs, taking 15 years of research and technical innova-
tion to reach this standard.  
 
1.5.2 PREDICTIVE INFORMATION IN CTCs 
It already says something that there is an approved system for CTCs detection, and as all 
new technologies and methods, the price at first is high but eventually it will become more 
accessible as the understanding of its current results are used to make it more efficient, sen-
sitive and simple. CTCs are important because they render towards phenotypic and genetic 
heterogeneity of tumour tissue and scientists have been able to grow them in vitro, which 
gives them a significant value for individualized analysis; like learning the effects of drug 
reactivity (Puche-Sanz et al., 2020). The true value of CTCs relies on their promising diag-
nosis. Another good reason to study CTCs is that they range in size from 4 to 20 μm, they 
can also be found in clusters of 2 to 100 cells and range in size from 10 to 100s μm in 
diameter (Sun et al., 2018). Since CTCs are a heterogenous population this can be relevant 
for their characterization and make a difference when a method is used for their isolation. 
CTCs stain positive for epithelial cell adhesion molecule. In table 3 there is a comparison 
between the advantages and difficulties CTCs face. 
 
Table 3. CTCs pros and cons.  
 
Approaches Limitations 
Competent for RNA and protein expres-
sion. 
Problematic long-term storage for analysis 
later on. 
Categorization of tumour heterogeneity. 
 
Complex and pricey detection but has a 
standardized and validated system. 
Expectation of cultures and susceptibility 
testing. 
Challenging clinical execution due to high 
technical and economic costs and low-




When cancer cells are shed into the bloodstream they can undergo EMT, this will make 
epithelial cells lose their phenotype, losing their cadherins and eventually making them lose 
into the blood circulation. What happens next is that they transition to mesenchymal pheno-
type. Along this transition, the expression of CKs and EpCAM is lost together with the mor-
phology of epithelial cells (Geeurickx and Hendrix, 2019). Some studies account to mesen-
chymal CTCs to induce the formation of metastases (Bourcy et al., 2016). Physicians have 
come to the conclusion that EMT is required in CTCs to adapt into the bloodstream environ-
ment and therefore survive in it enough to metastasize in other organs (Puche-Sanz et al., 
2020). Some studies have found that CTCs in circulation have a much longer durability than 
blood cells (Bagnall et al., 2015). This gives another point in favor to studying and isolating 
CTCs efficiently.  
Circulating tumour cells may be the most constituted detective target in liquid biopsy. First, 
they can be of significant value to detect early cancer along with some directional hints for 
treatment and insight to precise location of tumorigenesis. The presence of even one single 
CTC cluster in blood when taking samples has proven that survival rates reduces in cancer 
patients, giving it a high value for studying precision oncology (Sun et al., 2018). However, 
the challenges that CTCs detection encounters are still relatively relevant. First, the amount 
found is considerably low and therefore needs methods of higher affinity and sensitivity, not 
to mention that there needs to be enrichment to improve the before mentioned. Secondly, 
there is a time gap to complete the sampling in a highly efficient manner because of its life 
time.  
 
1.5.3 TECHNOLOGICAL CONSIDERATIONS 
Circulating tumour cells detection is of extreme importance to make precision oncology a 
reality. In the last decade one can see the increment of research published online of new 
ways to detect CTCs with different technologies. In part, time has allowed CTC detection to 
become promising and attractive to physicians and scientists but the truth is that with time 
advances came in medicine, biology, chemistry, oncology and material sciences that have 
made it possible to see advancement in this field. Presently, CTCs are being detected using 
epithelial markers. For this reason, CTCs which do not have an epithelial constitution are 
not being detected, and as mentioned before, that is probably because it has undergone EMT. 
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Research is working towards making sure that all CTCs are detected, independent of epithe-
lial, in novel techniques. Another thing that current methods need to improve is capturing 
viable CTCs, as many are lost in the process and the count is already very low in circulation 
(Millner et al., 2013).  There is heterogeneity within CTC populations, so far some of the 
cancer cells identified are: mesenchymal tumour cells, stem tumour cells, epithelial tumour 
cells, epithelial to mesenchymal hybrid tumour cells and clusters of tumour cells known as 
circulating tumour microemboli (CTM) (Laget et al., 2017). However, recent studies point 
to this heterogeneity being greater and different between patients and even from a single 
blood sample (Bankó et al., 2019). Apart from this complicating the capture of viable CTCs 
it requires new technologies and approaches to properly isolate them. Learning and identi-
fying the subtypes for CTCs will give physicians a detailed status of the patients risk for 
metastasis as well as an individualized approach to fight the illness; not to mention that it 
could have the potential to reveal the site where the metastasis will form next (Millner et al., 
2013). To date, the quantification of CTCs is used to evaluate the efficacy of therapy. Since 
the correlation between disease state and CTCs numbers are proportionate. Therefore, if the 
analysis shows a lower number of CTCs on the blood after treatment, physicians can assume 
that the treatment is indeed working. To prevent EpCAM mediated cell capture from a partial 
issue or situation, that is, to improve its affinity, there can be used specific biomarkers like 
antibodies or aptamers targeted toward specific markers (Sun et al., 2018). CTCs can be 
isolated using density gradient centrifugation, like Ficoll™ or Percoll® gradients, and they 
fractionate together with peripheral blood mononuclear cells; their estimated density ranges 
approximately from 1,064 to 1,065 g/cm^3 (Sun et al., 2018). 
Detection technologies use indicators for CTCs detection, such as: purity, recovery rate and 
limit of detection (LOD) (Gao et al., 2020). Purity makes reference to the percentage of 
enriched CTCs to the total number of cells in the enriched samples. The recovery rate will 
be the number of the enriched CTCs to the total amount of CTCs in the blood in percentage, 
it is sometimes referred to as enrichment efficiency or capture efficiency in other literatures. 
The LOD sets the limit of the CTC concentration that could potentially be detected in the 
blood. Due to their extreme rarity, most methods require an enrichment step antecedent to 
detection of CTCs, this step is meant to separate in fractions the CTCs from unwanted cel-
lular components of blood and blood plasma and ready for detection techniques. Cells can 
be separated by their physical properties such as cell size, migratory properties, density and 
protein expression (O’connor, 2016). Cancer care institutions have not yet acquired CTC 
technologies into their guidelines for clinical care, because although they have prognostic 
23 
 
value, there has not been any improvement towards survival rate in cancer patients (Yin et 
al., 2019). Presently, the clinical function of CTCs is based on enumeration of CTCs with 
an epithelial phenotype, with research clinicians have discovered that instead of just focusing 
on enumeration technologies they can expand to characterization technologies and get some-
thing that is more concrete for clinical utility (Ferreira et al., 2016). With the characterization 
of CTCs clinicians could instead provide the patients with a relative distribution of CTCs 
and their metastatic potential, allowing physicians to veraciously predict outcome both se-
lecting the most personalised treatment and for future metastatic sites (Millner et al., 2013). 
CTC detection methods are currently being used mainly for research purposes despite their 
potential role in cancer well-being. Unfortunately the lack of standardized technologies pre-
vents physicians to obtain congruent data as the techniques used are different as well as the 
technological platforms (Bankó et al., 2019). 
 
1.5.4 ENRICHMENT 
It is most common that CTCs are enriched to be isolated for the subsequent phenotype iden-
tification and molecular analysis. Enrichment of CTCs can be done in two different ways, 
positive and negative enrichment. In 2004 the first negative enrichment technology was de-
veloped to enrich rare cells in blood (Kowalik et al., 2017). The negative enrichment consists 
in capturing non-target cells or healthy blood cells and wash out with a solvent target cells 
or CTCs in this case. Contrary to positive enrichment, which does the opposite, it elutes 
healthy blood cells and captures CTCs. Moreover, positive enrichment can be divided into 
two categories: in vitro enrichment and in vivo enrichment. CTC detection without an en-
richment step is known as direct detection and it can be done with two technologies, surface 
enhanced Raman spectroscopy (SERS) and line-confocal microscope (Shen et al., 2017). 
Understanding the explicit partiality that prevents different enrichment methods to get stand-
ardized will help significantly towards working on technologies that focus on different CTC 
subpopulations. Antigen-free approaches have been shown to be more favorable in isolating 
CTCs now that clinicians have discovered that the heterogeneity in CTCs is greater than first 
thought (Salvianti et al., 2020). The presence of CTMs or CTC clusters, is another biological 
sign that gave clinicians insight that enrichment technologies had to peruse another direction, 
researchers got their attention to this when they found that CTMs have the ability to resist 
apoptosis and form metastasis at a significantly higher rate than individual CTCs (Ferreira 





To compare different detection methods and describe device execution, the following pa-
rameters are taking into account in table 4.   
 
Table 4. Parameters for CTC detection (Modified after Bankó et al., 2019).  
 
Capture efficiency  Represent the efficiency by which a device cap-
tures CTCs from a sample. 
Purity  Ability of the device to specifically capture 
CTCs within a background of contaminating 
cells.  
Enrichment  Refers to the factor increase of tumour cells in 
the sample volume relative to a background of 
other cells (primarily leukocytes) before and af-
ter running the sample.  
Throughput Volume or number of cells in a sample that a de-
vice can process in a unit of time. 
Cell viability  Percentage of CTCs that remain alive after en-
richment. 
Release efficiency Percentage of cells that are recovered from the 
device. 
 
The technologies for CTC detection must be repeatable, rapid, reliable, cost-effective and 
capable to wide-ranging use and extensive production. They also need to be able to capture  
the extremely rare cells, the sample for that success should be around 7,5ml (Ferreira et al., 
2016). The beforementioned is what the technologies are stating as the basic requirements 
to evaluate and compare the outcomes of CTC detection. However, the identification of can-
cer cells in blood raises a challenge because of its similarities to non-tumour circulating rare 
cells (CRC) also found in samples, like: epithelial-atypical cells, normal stem cells, epithe-
lial-normal cells, endothelial cells and physiological-state dependent cells (i.e., fetal cells in 
women during and after pregnancy or giant monocytes) (Laget et al., 2017). Another chal-
lenge is the pre-treatment done to blood prior to measuring it, recent studies have shown that 
lysis or centrifugation may considerably lower the number of CTC in the samples. For this 
reason technologies that use whole blood samples are rising but still have to overcome some 
of the challenges that come without pre-treatment, devices must come in various pore sizes 
and shapes or have fluid-assisted separation technology (Bankó et al., 2019). 
The more clinicians are testing and trying different methods they realise how this topic is 
everchanging and giving new insight on approaches required for efficient detection of CTC 
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and their subpopulations. For example, in measurements of cell deformability and drug re-
sponse they realised that it is relevant to have viable cells, thus two supplementary criteria 
were added to the parameters for CTC detection; release efficiency and cell viability 
(Ferreira et al., 2016). Also, the change from CTC enumeration to molecular characterization 
will require techniques to provide a greater recovery rate. For now, CTC capture focuses on 
strategies to sort cells by their size, deformability, electrical charge, density and tumour cell 
surface marker expression (Ferreira et al., 2016). In reality, there is not a technology that is 
suitable for or used in all circumstances and the different approaches should be taken into 
account according to the type of cancer being studied.  
 
1.5.6 CTC MICROFLUIDIC-BASED APPROACHES 
In the last decade, microfluidic-based approaches have significantly improved the applica-
tions of sample preparation, enrichment and point-of care (POC) diagnostics. They are first-
class miniature tools for studying tumours and they are ideal for single cell sequencing ap-
plications for ultimately understanding cancer (Menon et al., 2019). In diagnostics it makes 
it possible for extremely accurate fluid manipulation and control, this allows for higher 
throughput and faster sample processing. Microfluidic-based technologies have thus been 
attractive for having the quality for early diagnosis and real-time monitoring together with a 
remedial efficacy of the illness. The technology is used to sort through liquid biopsy samples 
and help identify specific cancer biomarkers, it can discriminate between cells at the single-
cell level and enable separation and detection of CTCs, which is not possible with bulk tech-
niques (Sun et al., 2018). 
It was in 2007 when CTC isolation was first demonstrated using a microfluidic-based ap-
proach with the CTC-chip and it was because of its success in identifying CTCs in >99% of  
the patient samples that it gave clinicians a focus in improving and developing further mi-
crofluidic-based systems to isolate and detect CTCs (Sun et al., 2018). The focus clinicians 
can use for CTC isolation strategies rely on biological and physical properties of cells, that 
can provide unique information to distinguish malignant cells from other haematological 
cells present in the heterogeneity of blood samples, like white and red blood cells. Tech-
niques can be based on immune-affinity capture of CTCs, i.e., on antibody-antigen interac-
tions using EpCAM as target; working on exploiting cell surface markers making it possible 
to identify CTCs related to tumorigenesis. Or the other technique, known as label-free, focus 
on unique physical characteristics like shape, size, deformability and conditions of mi-




1.5.6.1 LABEL-FREE BASED APPROACH 
The detection of biomolecules or cells at low abundance is extremely difficult. Label-free 
techniques are a promising option for biomolecule detection based on its advantages, includ-
ing low-cost and easy operation. Meanwhile, microfluidic systems have been utilized for 
analyzing single molecules or cells at low sample volumes. Combining these two techniques 
may therefore offer a promising strategy to separate and detect low-abundance biomolecules 
or cells in complex samples (Leung et al., 2019).  There has been demonstrated that the 
label-free path can separate CTCs by hydrodynamic chromatography, filtration and dielec-
trophoresis methodologies with the downsize that they do not attain a high purity of CTCs 
and cell viability is compromised for further analysis (Chen et al., 2020). The separation of 
CTCs in a label-free microfluidic system depends on physical differences of the cells, such 
as its shape, size, electrical impedance or polarizability. These at the same time can be clas-
sified into three methods, kinetic separation, equilibrium separation and namely elution sep-
aration (Leung et al., 2019). Nevertheless, this technique comes with many challenges and 
still requires a covalently-attached label (can be an enzymatic or a fluorescent label), to de-
tect the targeted cell or molecule; at the same time this poses disadvantages like the alteration 
of binding affinity and electrophoretic mobility change, interference of fluorescence signal 
or loss of numerical response; moreover, fluorescent labels could have damaging effects on 
the assay detection time (Leung et al., 2019). 
 
1.5.6.2 IMMUNO-AFFINITY BASED APPROACH 
The biological differences between cells can also be used to differentiate normal cells from 
CTCs. Incorporating microfluidic systems to this separation technique can increase the iso-
lation of CTCs from millions of normal cells in a blood samples due to the force generated 
by blood flow in the microchannel allowing the separation of intact CTCs for post-analysis 
and culture (Silva et al., 2020). Typically, the devices to capture CTCs with immune-affinity 
approaches need to get stained and evaluated on-chip or lysed to extract nucleic acids or 
proteins, the final purpose being the analysis of intact isolated CTCs. From 2007 clinicians 
have been incorporating techniques and technologies to improve and enhance previous de-
signs. Recently, the rise to incorporate more than two approaches became trending to ac-
complish a more specific immune-affinity capture (Sun et al., 2018). Currently, a novel 3D 
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printed microfluidic device that can increase the surface area and fluid flow manipulation 
which results in higher CTC capture efficiency has been proposed. This device works with 
anti-EpCAM antibodies to isolate CTCs from blood samples, despite it is quite complicated 
to efficiently fabricate 3D structures with these beforementioned features to isolate CTCs, 
Chen et al. demonstrated that it is possible (Chen et al., 2020). 
 
1.5.6.3 FUTURE DIRECTION FOR CTCs SEPARATION USING MICROFLUIDIC 
SYSTEMS 
 
Despite the advantages that incorporating microfluidic systems with isolation techniques has 
increased the efficiency of CTCs capture it has not been widespread for clinical or commer-
cial applications. This can be judging from the complexity to translate laboratory standardi-
zation to pre-clinical or clinical devices followed by the unwillingness of places to adopt 
novel and unacquainted technologies (Sun et al., 2018). A combination between immune-
based and label-free based techniques in microfluidic devices has been looked into and re-
sults from several studies point out to the potential it has to achieve a more specific selection 
of CTCs, a higher efficiency and faster categorization with increased recovery rate and purity 
(Silva et al., 2020). Additionally, these biological and physical principals can be integrated 
into multi-step procedures on progressive nanotechnologies and microfluidic systems to ac-
complish high-standard capture and analysis of CTCs (Yin et al., 2019). With the develop-
ment of new devices and methods, it may be that label-free technologies could compete with 
affinity-based methods providing superior performances, regarding a higher throughput. A 
limitation related to microfluidics is primarily low throughput and the ability to process large 
amounts of samples and detect viable number of CTCs for post-analysis  (Sun et al., 2018). 
One disadvantage of label-free separation is the low selectivity achieved compared to affin-
ity-based methods (Leung et al., 2019) but on a brighter note it carries the potential to isolate 
a larger number of cells (Silva et al., 2020). Thus, these setbacks are the reason a combina-





2 AIM OF THE THESIS 
 Review the potential of liquid biopsy as a test for cancer diagnosis. 
 Overview of biomarkers, such as CTCs and cfNAs to analyse tumorigenesis.  
 Technological approaches and research on better understanding cancer. 





From venous blood clinicians can isolate, identify and measure biomarkers such as CTCs 
and cfDNA; this at the same time contains in patients with cancer ctDNA and cell-free RNA 
(cfRNA). cfRNA is a mixture of small RNAs but it also contains EVs. These analytes carry 
genetic and epigenetic information about tumorigenesis or metastases which can be studied 
by scientists to understand the cause and effect of cancer. The studies are carried out by 
analyzing a blood sample of around 7,5ml through a test known as liquid biopsy (Marrugo-
Ramírez et al., 2018). A relatively high amount of blood is required giving the extreme rarity 
of these biomarkers, where the occurrence or ratio can be from one to a million or even a 
billion if we compare it with other blood cells (Dive and Brady, 2017). However, the clinical 
utility of liquid biopsy has not reached to something concrete to date, as many challenges 
are presented by the everchanging understanding of the biomarkers. Techniques and proto-
types continue to surge as research continuously increases throughout the years, which indi-
cates that this test will reach fruition in the coming years, transforming overall the healthcare 
system for people with cancer. The goal of liquid biopsy is to determine patient prognosis, 
be able to monitor tumour recurrence and responses to therapy in real-time, identify new 
drug target mechanisms and make clear and comprehensible in this way drug resistance; in 
general learn about tumorigenesis and metastasis progression (Siravegna et al., 2019). While 
traditional biopsies are still clinically relevant and is the test being carried out currently, it 
may be obsolete in the future once liquid biopsy reveals the beforementioned including that 
it is a non-invasive (or minimally) test, contrary to traditional biopsy which is not always 
feasible giving the nature or location of the tumour.  
CTC-based liquid biopsy is a major trend between all biomarkers as it has demonstrated the 
detection of early cancer giving the characteristics of CTCs which are the precursors of the 
illness. In the near future it is expected by repeated sampling that the molecular profile of 
CTCs can expand for the establishment of CTC cultures which will allow in-depth or intrin-
sic characterization as of today very little is known at the single-cell level and its mechanisms 
of survival in the bloodstream. Ex vivo analysis will be needed to reach the understanding of 
CTCs heterogeneity and their specific advantages for precision oncology. The evidence dis-
closes that the enumeration of CTCs can be used to predict, monitor and understand post 
treatment relapse of cancer (Bankó et al., 2019). CTC isolation and detection is normally 
done by both enrichment and detection. Enrichment step is focused on approaches based on 
the size, the density or immunomagnetic and microfluidic properties whereas detection step 
is protein or nucleic acid based (Lowes et al., 2016). It is true that both CTCs and cfDNA 
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have the potential to provide prognostic insight to physicians based on the quantity detected 
in the sample, however cfDNA has a downsize when it comes to differentiating it from 
ctDNA (cfDNA can originate both from tumour cells or other cell types) and it is key to 
evolve the study of single gene testing to multigene panel testing which ideally will capture 
a whole or at least better picture/exposure of the tumour genome. Detection of cfNAs holds 
a promising approach for tumour diagnosis, however there is not enough knowledge in the 
field and the lack of clinical studies are preventing the rise of these biomarkers. For now, 
these rely on literature and future willingness of physicians to invest and examine validated 
methods for their detections and understanding of their characteristics. With current technol-
ogies and knowledge it is hard to name a superior biomarker since as mentioned earlier, both 
have equivalent and comparable utilities in precision oncology. Further research is required 
to conclude this but there might be a scenario where one is better than the other according to 
the type of cancer or stage in which it is required. 
In regards to the technological requirements for cfDNA and CTCs, both require ultra-sensi-
tive detection techniques but CTCs also need capture implementation. Additionally, cfDNA 
has the advantage of being able to get stored for analysing at some eventual time giving it a 
possibility to have a bank whereas CTCs need to be processed in a timely manner (Lowes et 
al., 2016). On another note, research showed that unlike cfDNA, CTCs may be evaluated at 
the single cell level (Lowes et al., 2016). Another fact is that most studies of these bi-
omarkers are observational research, where the methodologies, cancer type and stage vary, 
steps and interpretations are always a variable thus it is important that in the future results 
are based on the scientific method. Microfluidic-based systems have effectively demon-
strated a fast and trustworthy model for isolating CTCs however a combination of several 
detection technologies show a higher efficiency as it can overcome individual technique 
challenges. The focus needs to be on developing technologies that result in high viable cells 
as of today a great number is lost through both pre-treatment and treatment steps (Vera-
Ramirez, 2020). As studies continue to process new outcomes, it will be easier for clinicians 
to understand that biomarker selection is indispensable along the proper tools and technolo-
gies to properly isolate and have success in presenting their clinical advantage. 
 
Microfluidic-based approaches may have a superior approach based on their miniature and 
unique flow pulsation compared to conventional approaches. However, it still requires to be 
combined with other techniques and methods that increase purity as of now it shows effi-
ciency in targeting extremely rare cells with high sensitivity. The advantages these systems 
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will contribute to detection, separation and analysis are such like: capacity for enough vol-
ume samples, multiplexing capabilities, time-efficient processing and large surface area-to 
volume ratio. The integration of microfluidic systems with technologies (electrical biosen-
sors, mechanical sensors and photonic sensors) will allow the development of portable diag-
nostic devices through parallelization (Leung et al., 2019). Affinity-based approaches mostly 
focus on EpCAM because this antigen is over-expressed in a variety of cancers like: lung, 
mammary, bladder, intestine, colon, etc., (Keller et al., 2019). Alternatively, specialized 
markers may also be used for other cancer types, like prostate-specific membrane antigen 
(PSMA) (Yin et al., 2019). Label-free techniques with integrated microfluidic chips allow a 
greater throughput compared to affinity-based methods resulting in higher CTCs for post-
analysis, this may be due to the physical properties of CTCs where compared to white blood 
cells (~7-15 µm) and red blood cells (~6-8 µm) they are relatively larger (~17-52 µm) effec-
tively accomplishing separation through size differences as a parameter (Silva et al., 2020). 
Nevertheless, improvement in this technique is vital to deal with the heterogeneity in CTC 
subpopulations to avoid non-specific capture. To the best of my understanding, microfluidic 
technologies are in the majority still deriving from an experiment or concept perspective, 
several designs are feasible but the translation to these systems are still limited to tangible 
marketed tools. To reach this point it is essential that scientists, clinics and governments 
considerably invest for standardization, fabrication and repetition of studies as well as the 
development of new technologies of genome sequencing, single cell analysis, molecular im-
aging, nanotechnology and so on.  
 
The CellSearch® system is the only approved FDA method to date for CTC analysis in colon, 
prostate and breast metastatic cancers but many other approaches are available for testing 
(Romay et al., 2019). This is given that the translation of these approaches from laboratory 
to clinical practice requires significant validation and time. The CellSearch® system is not 
microfluidic-based and instead it focuses on the separation and imaging of target cells by a 
combination of magnetic nanoparticles that differentiate CTCs from other cells (Menarini 
Silicon Biosystems, 2020). Also, it is a discrepancy that being from 2004 it has not adapted 
the new discoveries in the field. In short, there is a wide variety of isolation technologies and 
products in development, which makes it complicated to pass judgment and compare be-
tween each other or even propose a combination of these technologies to my knowledge. 
Furthermore, there is a vast mixture of techniques and results based on different cancers, 
patients, methods and interpretations and in order for this to become standardized reliable 
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data is needed. However, I predict that CTC isolation will continue to evolve according to 
new discoveries and current techniques will become obsolete or adjust for capturing different 
cells for other medical fields. Many papers focus on these evaluations and can be looked at 
into more detail, however, despite the advantages beforementioned in both CTCs and ctDNA 
changing clinical care in precision oncology, neither tests are used in cancer-care quite yet, 
but it is something that will come in time once their clinical utility is proven and efficient 






































The emerging need to reform precision oncology has significantly shown advancements in 
the field with promising outcomes, from diagnosis to treatment care. While traditional bi-
opsy holds a significant value on the histology of malignant tumours it is not always viable 
to access them giving their nature or location, so the rise of liquid biopsy will solve these 
challenges in the coming years once the test is proven to reveal the heterogeneity and char-
acteristics of tumour-specificity. Liquid biopsies are meant to provide early detection infor-
mation as well as repeated testing during the course of the illness to keep track of therapy 
response and expand the knowledge of cancer development by allowing further research of 
specific biomarkers; in the case of CTCs, it can be a source for in vitro cultures that allow 
in-depth molecular characterization. However, the true nature and heterogeneity of CTC 
populations is still not fully understood and requires extended evaluations to improve clinical 
care. Evidence points out to a correlation between CTCs surviving in the bloodstream and 
the formation of metastasis so it has an increased awareness value for prediction, monitoring 
and progression of cancer patients. At the same time, the analysis of cfNAs, which are re-
leased from tumour cells, are also meant for tumour diagnosis. However, this area has insuf-
ficiently powered studies carried by small study populations and uncontrolled methods 
which prevents them from validated and reliable accountability for clinic care. The field of 
microfluidics continues to improve and offer CTCs isolation for post-analysis purposes, 
however the current designs still face challenges that prevents the techniques to be com-
pletely efficient in capturing and isolating a great number of viable cells. Considering the 
extreme rarity of CTCs in the blood it is fundamental that a combination of several detection 
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A malignant tumour formed from glandular 
structures in epithelial tissue.  
Cadherins 
Group of proteins that mediate the calcium-
dependent adhesion of cells with each other. 
Aneuploidy 
The condition of having an abnormal 
number of chromosomes in a haploid 
set. 
Graft hybrid 
A hybrid plant that is produced by grafting 
and that exhibits characters of both the stock 
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